Kalaris Therapeutics (KLRS) Return on Equity [ROE] (2020 - 2026)
Kalaris Therapeutics' Return on Equity [ROE] was -75.67% in Q2 2026, up 41.05 percentage points from -116.73% a year earlier but down 11.03 percentage points from the prior quarter.
Powered by 
Analysis
Kalaris Therapeutics (KLRS) Return on Equity [ROE] (2020 - 2026) Analysis & Trends
For FY2023, Return on Equity [ROE] at Kalaris Therapeutics came in at -212.16%, down 137.14 percentage points from FY2022.
- Return on Equity [ROE] has now declined for three consecutive years, with a three-year change of -165.88 percentage points (FY2020 to FY2023).
- In earlier years, Return on Equity [ROE] was -75.02% in FY2022 (-15.55 pp), -59.47% in FY2021 (-13.19 pp) and -46.28% in FY2020.
- Quarterly Return on Equity [ROE] has moved between -254.32% (Q4 2023) and -48.54% (Q3 2021) over five years.
- The best year-over-year quarter for Return on Equity [ROE] over five years was Q2 2026 (a gain of 41.05 percentage points); the worst was Q4 2023 (a drop of 183.69 percentage points).
- Per Business Quant data, KLRS's Return on Equity [ROE] in the three quarters before Q2 2026 was -64.64% (Q1 2026), -78.88% (Q4 2025) and -92.34% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 82.09% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 25.32% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | - |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 7.21% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 84.40% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 21.39% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 83.75% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -18.38% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 4.97% |
| 10 | Kalaris Therapeutics | 64.27 Mn | 64.27 Mn | - | -75.67% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -75.67% |
| Mar 31, 2026 | -64.64% |
| Dec 31, 2025 | -78.88% |
| Sep 30, 2025 | -92.34% |
| Jun 30, 2025 | -116.73% |
| Dec 31, 2023 | -254.32% |
| Sep 30, 2023 | -79.88% |
| Jun 30, 2023 | -79.18% |
| Mar 31, 2023 | -79.78% |
| Dec 31, 2022 | -70.63% |
| Sep 30, 2022 | -91.19% |
| Jun 30, 2022 | -109.20% |
| Mar 31, 2022 | -88.21% |
| Dec 31, 2021 | -69.18% |
| Sep 30, 2021 | -48.54% |
| Jun 30, 2021 | -36.84% |
| Mar 31, 2021 | -26.62% |
| Dec 31, 2020 | -19.25% |
| Sep 30, 2020 | -35.69% |
API Access
Kalaris Therapeutics Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=KLRS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "KLRS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=KLRS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();